The Centers for Disease Control and Prevention might soon limit its guidance for who should receive a coronavirus booster ...

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...

Secretary of Defense Pete Hegseth revealed Wednesday that letters were sent out to bring back American service members who ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Sugar coatings aren't only for candies; they also help viruses, like the ones that cause COVID-19, hide from their hosts' ...

Gardiner Harris’s investigation of Johnson & Johnson explores the many ways corporate greed and weak regulations fail to ...

The White House rolled out a new COVID.gov website showing the “true origins" of the coronavirus after Democrats and the ...

While data was not available on how many young people had already received their second dose of the coronavirus vaccine, more than 289,000 people aged 12 to 19 had received at least one.

As the 130+ vaccine candidates currently in development progress through clinical testing, a key question for their manufacturers is how COVID-19 might be changing the equation when it comes to ...

Last week it emerged that AZ had put the trial on a temporary hold because of a potential safety issue involving one patient in the UK, who had become ill after taking the vaccine, codenamed AZD1222.